Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions
Open Access
- 18 November 2019
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (11), 2016
- https://doi.org/10.3390/jcm8112016
Abstract
Percutaneous cardiovascular interventions have changed dramatically in recent years, and the impetus given by the rapid implementation of novel techniques and devices have been mirrored by a refinement of antithrombotic strategies for secondary prevention, which have been supported by a significant burden of evidence from clinical studies. In the current manuscript, we aim to provide a comprehensive, yet pragmatic, revision of the current available evidence regarding antithrombotic strategies in the domain of percutaneous cardiovascular interventions. We revise the evidence regarding antithrombotic therapy for secondary prevention in coronary artery disease and stent implantation, the complex interrelation between antiplatelet and anticoagulant therapy in patients undergoing percutaneous coronary intervention with concomitant atrial fibrillation, and finally focus on the novel developments in the secondary prevention after structural heart disease intervention. A special focus on treatment individualization is included to emphasize risk and benefits of each therapeutic strategy.This publication has 136 references indexed in Scilit:
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingCirculation, 2012
- Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve ImplantationJournal of the American College of Cardiology, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeThe New England Journal of Medicine, 2012
- Silent Cerebral Infarcts in Patients With Pulmonary Embolism and a Patent Foramen OvaleStroke, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2007
- Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEuropean Heart Journal, 2006
- Variability in platelet responsiveness to clopidogrel among 544 individualsJournal of the American College of Cardiology, 2005
- Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study.Circulation, 1984
- Nonoperative Dilatation of Coronary-Artery StenosisThe New England Journal of Medicine, 1979